Merck and Moderna Prepare Melanoma Vaccine Filing
The companies plan to submit their mRNA melanoma vaccine for regulatory review following positive Phase 3 trial results.
Updated on Oct. 20, 2026 in Cancer
Live Poll
Do you feel optimistic that new cancer treatments will be available to you when needed?
Merck and Moderna are advancing toward an FDA filing for their experimental mRNA cancer vaccine. The treatment is designed to be used in conjunction with the immunotherapy drug Keytruda to prevent cancer recurrence in patients who have undergone surgery for melanoma.
Why it matters
This therapy represents a personalized approach to oncology by training the immune system to recognize specific mutant proteins found in a patient's own tumor. The goal is to provide a durable secondary defense against high-risk melanoma following the surgical removal of cancerous tissue.
The investigational vaccine, intismeran autogene, uses an algorithm to select up to 34 mutant proteins from a patient's tumor sample. Data from the earlier Phase 2b KEYNOTE-942 trial previously demonstrated a 49% lower risk of recurrence or death at five years.
The players
Merck
This global pharmaceutical company is a major producer of immunotherapy treatments and vaccines.
Moderna
This biotechnology company focuses on the development of messenger RNA (mRNA) therapeutics and vaccines.
The details
The treatment functions by delivering mRNA instructions to the immune system, while Keytruda removes the brakes on immune cells to boost their cancer-fighting capacity. The companies reported no new safety signals during the Phase 3 INTerpath-001 trial, which studied patients with stage IIB to IV cutaneous melanoma.
Timeline
2019: A trial participant received their high-risk melanoma diagnosis.
2023: Over 1.5 million people in the U.S. were living with melanoma.
August 2026: Phase 3 trial results indicated a delay in cancer recurrence.
October 15, 2026: Company leaders discussed the program at the STAT Summit in Boston.
Health Landscape
The INTerpath-001 trial represents a significant step in mRNA cancer immunotherapy, moving from early Phase 2b indicators to a large-scale Phase 3 regulatory milestone. This development follows a broader industry trend of integrating personalized genetic targeting with established immunotherapy drugs to improve patient outcomes.
If approved, this personalized vaccine could provide a new, targeted treatment option for patients recovering from surgically removed stage IIB to IV melanoma. Patients should discuss potential clinical trial participation and future availability with their oncologists as data continues to emerge.
The takeaway
This news highlights how mRNA technology is being leveraged to create highly specific, personalized cancer vaccines. Patients at high risk for recurrence should continue monitoring clinical developments as the companies prepare for formal regulatory submissions.
Further reading
For more information on current treatment trends, visit the United States Cancer page.
Source note: This article includes information reported by Medical Daily.
Live Poll
Do you feel optimistic that new cancer treatments will be available to you when needed?
